Product Information
Anti-Cancer Scientific Research
Descripción
BEING THE PRESIDENT OF AMERICAN INTERNATIONAL TUMOR INSTITUTE OF TRADITIONAL CHINESE MEDICINE, SHE HAS BEEN THE PRESIDENT OF HARBIN SHENKANG TUMOR INSTITUTE OF TRADITIONAL CHINESE MEDICINE IN CHINA AND MEMBER OF WORLD MEDICAL INTITUTE, PRESIDENT OF HEILONGJIANG SHENKANG TUMOR INSTITUTE OF TRADITIONAL CHINESE MEDICINE. SHE HAS BEEN FOR A LONG TIME AND HAS ACHIEVED A GREAT ACHIEVEMENT. DR WANG SHUXIA STARTED HER MEDICAL STUDY SINCE SHE WAS 12 YEARS OLD LEARNING FROM HER GRANDFATHER.
1975, SHE HAS TRAVELD ALL OVER THE COUNTRY AND FOUND OUT MORE THAN 100 KINDS OF SNAKES. SHE HAS CONCERNED STUDIES ON THESE SNAKES BY DIFFERENT KINDS, PARTS AND ORGANS AND HAS COLLECTED FROM SANKES IMMUNOCOMPETENT COMPONENTS FOR ANTITUMOURS.WITH THE IMMUNOCOMPETENT PARTS ADDED WITH COMPOTENTS OF ANTITUMOURS COLLECTED FROM TRADITIONAL CHINESE MEDICINE, SHE WORKED OUT SNAKE-EXTRACT ANTICANCER INJECTION AND SHENGKANG CAPSULE 01, WHICH , IN VIEW OF DOCUMENT SEARCH, IS THE FIRST NEW ANTICANCER MEDICINE COMBINING SNAKE WITH TRADITIONAL CHINESE MEDICINE WITH MORE THAN TEN THOUSAND TESTS ON ANIMALS FOR YEARS. WITH MORE THAN TEN THOUSAND CLINICAL PRACTICES ON EFFECTS, ESPECIALLY FOR LUNG CANCER, LIVER CANCER, LYMPH CANCER, BREAST CANCER, CERVICAL CANCER, GASTRIC ACNCER AND INTESTINAL CANCER AT THE MEDIUM AND LATER STAGES. A PERIOD OF TREATMENT IS 25 DAYS.
IN 1987, THE PHARMACOLOGICAL TESTS DONE BY HEILONGJIANG TRADITIONAL CHINESE MEDICINE INSTITUTE SHOWED THAT THE SNAKE-EXTRACT ANTICANCER INJECTION ENJOYS A 67% OF INHIBITION RATE WHEN USED FOR LUNG CANCER FOR LUNG CANCER OF MOUSE; A 63% INHIBITION RATE FOR ASCITIC FLUID CANCER, AND A 59.8% OF INHIBITION RATE FOR U14. THE MEDICINES CAN NOT ONLY INHIBIT CANCERS, BUT ALSO HAVE THE FUNCTION OF EASING PAIN WITHOUT IRRITABILITY, STIMULATION. ON MARCH 18TH, 1992, THE MEDICINE GAINED THE CHINESE PATENT OF INVENTION. THE SHENKANG CAPSULE 01 INVENTED BY DR. WANG SHUXIA HAS A SPECIAL CURATIVE EFFECT ON THE WIDE METASTASIS OF LUG CANCER, GASTRIC CANCER, THYOID CANCER, INTESTINAL CANCER, BLADDER CANCER AND STONE CANCER AT THE LATER STAGE. IN 1992, THE PHARMACOLOGICAL TESTS, DONE BY THE TUMOUR INSTITUTE OF THE CHINESE MEDICINE ACADEMY OF SCIENCE, SHOWED THAT THE MEDICINE HAD A TUMOR INHIBITION RATE OF 59.8% FOR ANIMAL H22 AND 45.7% FOR LOUIS HUNG CANCER, AND THE MEDICINE WAS APPROVED TO BE EXPORTED BY AUTHOR-ITY IN CHARGE OF MEDICINE.
Keywords
Comments
No record!
